Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alterations in Abdominal Blood Flows After Drinking Coffee.

Pharmacology research & perspectives·2026
Same author

Impact of the COVID-19 pandemic on clinical laboratories in Japanese hospitals and preparedness for the next pandemic: A nationwide questionnaire survey.

Diagnostic microbiology and infectious disease·2026
Same author

Quantitative analysis of the cell surface area of neutrophils in myelodysplastic syndromes/neoplasms.

Laboratory medicine·2026
Same author

Modified Psychosocial Assessment of Candidates for Transplantation Predicts Clinical Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation.

Transplantation and cellular therapy·2026
Same author

Autopsy case report of rapidly progressive iliopsoas abscess caused by <i>Escherichia coli</i> and <i>Prevotella bivia</i>.

Radiology case reports·2026
Same author

Evaluation of the detection performance of the RaST-TAS β-lactamase screening reagent kit based based on the DSTM principle for ESBL production.

Diagnostic microbiology and infectious disease·2026
Same journal

Transcriptomic profiling of an in vivo diffuse large B-cell lymphoma model reveals molecular programs underlying CNS dissemination.

Annals of hematology·2026
Same journal

A systematic review of 47 published cases of extramedullary hematopoiesis in myelofibrosis: clinical patterns, treatment responses, and prognostic implications.

Annals of hematology·2026
Same journal

A case report of CD4<sup>-</sup> CD8<sup>+</sup> CD56<sup>-</sup> TCRγδ<sup>+</sup> T-large granular lymphocytic leukaemia with severe aplastic anemia and a PNH clone.

Annals of hematology·2026
Same journal

An assessment of the effectiveness of hydroxyurea therapy in children and adolescents with sickle cell anaemia at Kenyatta National Hospital.

Annals of hematology·2026
Same journal

Allogeneic hematopoietic stem cell transplantation for a pediatric case of myelodysplastic syndrome with germline DDX41 mutation.

Annals of hematology·2026
Same journal

Clinical and prognostic significance of concomitant autoimmune disease in patients with myelofibrosis.

Annals of hematology·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

Assessment of Human Natural Killer Cell Events Driven by Fc&#947;RIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Interleukin-6 levels decrease following rituximab treatment but increase following tocilizumab treatment.

Makoto Ide1,2, Tetsuya Fukumoto3, Hiroaki Ohnishi3

  • 1Department of Hematology, Takamatsu Red Cross Hospital, 4-1-3 Ban-cho, Takamatsu, 760-0017, Kagawa, Japan. makoto13@smile.ocn.ne.jp.

Annals of Hematology
|June 13, 2026
PubMed
Summary
This summary is machine-generated.

This study compared rituximab and tocilizumab for idiopathic multicentric Castleman disease (iMCD). Rituximab reduced IL-6 and CRP levels, while tocilizumab significantly decreased CRP but elevated IL-6, indicating distinct biomarker responses in iMCD treatment.

Keywords:
Castleman diseaseIL-6RituximabTAFRO syndromeTocilizumab

Related Experiment Videos

Last Updated: Jun 16, 2026

Assessment of Human Natural Killer Cell Events Driven by Fc&#947;RIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Area of Science:

  • Hematology
  • Immunology
  • Pharmacology

Background:

  • Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder driven by chronic hypercytokinemia, with IL-6 central to its pathology.
  • C-reactive protein (CRP) is a common biomarker for IL-6 activity, but its interpretation can be complicated by IL-6 pathway blockade therapies like tocilizumab.
  • The effects of rituximab on IL-6 and CRP levels in iMCD are not well-characterized, necessitating direct comparisons with established anti-IL-6 therapies.

Purpose of the Study:

  • To compare the effects of rituximab and tocilizumab on serum IL-6 and CRP levels in patients with idiopathic multicentric Castleman disease (iMCD).
  • To investigate the distinct biomarker dynamics associated with each therapeutic approach in iMCD management.

Main Methods:

  • A retrospective study involving 17 iMCD patients (8 treated with rituximab, 9 with tocilizumab).
  • Serum IL-6 and CRP levels were measured before and after treatment.
  • Paired t-tests were used to assess within-group changes in biomarker levels.

Main Results:

  • Rituximab therapy showed a trend towards decreased IL-6 and CRP levels, though not statistically significant.
  • Tocilizumab therapy resulted in a significant decrease in CRP levels (p < 0.05).
  • Tocilizumab therapy led to a significant increase in IL-6 levels (p < 0.05), despite CRP reduction.

Conclusions:

  • Rituximab therapy appears to improve iMCD symptoms by reducing IL-6 levels.
  • Tocilizumab therapy demonstrates distinct biomarker dynamics, significantly reducing CRP while paradoxically increasing IL-6 levels.
  • These findings highlight differential biomarker responses to rituximab and tocilizumab, impacting the interpretation of treatment efficacy in iMCD.